Peey‐Sei Kok

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Anna K. Nowak, W. Joost Lesterhuis, Peey‐Sei Kok et al. · The Lancet Oncology · 2020 · 169 citations

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +7

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Yoland Antill, Peey‐Sei Kok, Kristy Robledo et al. · Journal for ImmunoTherapy of Cancer · 2021 · 120 citations · Full text

Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).

Yoland Antill, Peey‐Sei Kok, Kristy Robledo et al. · Journal of Clinical Oncology · 2019 · 55 citations

Tumor Biology, Lymphoid Neoplasia, Medicine +15

OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result

Anna K. Nowak, Peey‐Sei Kok, W. Joost Lesterhuis et al. · Journal of Thoracic Oncology · 2018 · 42 citations · Full text

First Line Chemotherapy, Oncology, Metronomic Therapy +6

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

Angelina Tjokrowidjaja, Sarah J. Lord, Thomas John et al. · Cancer · 2022 · 38 citations · Full text